Previous clinical studies revealed the significant efficacy of cancer therapies targeting EGFR in overall survival (OS), progression-free survival (PFS) and overall response (OR) in several types of cancers, including NSCLC, CRC, pancreatic cancer, breast cancer and SCCHN [75,76,77]. Here, EGFR is linked to breast cancer.